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The effective vaccines developed against a variety of infectious agents, including polio, measles, and hepa-
titis B, represent major achievements in medicine. These vaccines, usually composed of microbial antigens,
are often associated with an adjuvant that activates dendritic cells (DCs). Many infectious diseases are still in
need of an effective vaccine including HIV, malaria, hepatitis C, and tuberculosis. In some cases, the induc-
tion of cellular rather than humoral responsesmay bemore important because the goal is to control and elim-
inate the existing infection rather than to prevent it. Our increased understanding of the mechanisms of
antigen presentation, particularly with the description of DC subsets with distinct functions, as well as their
plasticity in responding to extrinsic signals, represent opportunities to develop novel vaccines. In addition,
we foresee that this increased knowledge will permit us to design vaccines that will reprogram the immune
system to intervene therapeutically in cancer, allergy, and autoimmunity.Introduction
Vaccines can be preventive or therapeutic. The word vaccination
was first used by Edward Jenner in 1796 to describe the injection
of smallpox derived from cows (L. vaccae, cow). Louis Pasteur
discovered that animals and people could be protected against
disease after exposure to attenuated microbes. Most, if not all,
preventive vaccines are designed to initiate protective humoral
immune responses. However, many pathogens, for which no
efficient vaccines are available, are still affecting mankind with
diseases such as human immunodeficiency virus (HIV)-induced
acquired immune deficiency syndrome, plasmodium-induced
malaria, virus-induced hepatitis C, andMycobacterium-induced
tuberculosis. Most of these appear to be chronic diseases for
which it is thought that strong cellular immunity, in particular
cytotoxic T cells, is necessary to eliminate the cells that are
infected with the causative agent. Thus, therapeutic vaccines
are needed to eliminate existing disease as much as prophy-
lactic vaccines that might block the initial infection. Vaccines
have yet to be developed in noninfectious settings, where they
have the potential to prevent and treat cancer, allergy, and
chronic inflammation.
A more detailed understanding of the mechanisms leading
to strong cellular immunity is necessary to enable rational
approaches to vaccine design. Two recent conceptual break-
throughs in this regard have been (1) our understanding that
dendritic cells (DCs) play a pivotal role in initiating the immune
response to foreign antigens (Figure 1) and (2) the realization
that adjuvants act primarily because they are DC activators.
Preventive vaccines are based on the concept of transitioning
from no immunity to immunity by generating new CD4+ or
CD8+ T effector cells by ‘‘priming’’ a new immune response.
Therapeutic vaccines in chronic infections (or cancer) have two
objectives: one is priming whereas the other is the modulation464 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.or reprogramming of memory cells, i.e., to transition from one
type of immunity to another (e.g., regulatory to cytotoxic). These
two types of vaccination might necessitate distinct approaches,
facilitated by exploiting the diversity of DCs including their
different subsets and functional plasticity.
The Challenge of Eliciting the Right Immune Response
The efficacy of vaccination is directly linked to the type and the
quality of immune responses elicited by a particular vaccine.
Indeed, generating the right class of immune response can be
a matter of life and death, perhaps best illustrated by leprosy
where the indolent tuberculoid form of the disease is character-
ized by a protective type 1 T cell (Th1 cell) response, whereas the
lepromatous form induces an often lethal type 2 (Th2 cell)
response.
The quality of CD4+ T cell immunity is essential for the quality
of effector cells such as antibody-secreting plasma cells and
cytotoxic CD8+ T cells. CD4+ T cells also appear necessary for
the efficient generation of memory CD8+ T cells (Janssen et al.,
2003; Shedlock and Shen, 2003; Sun and Bevan, 2003). CD4+
T cells display a broad spectrum of phenotypes, which is prob-
ably due to the priming by antigen-presenting cells (APCs),
most often DCs (Figure 2; reviewed in Bluestone et al., 2009).
Thus, in response to intracellular microbes, such as viruses
and certain bacteria, CD4+ T helper cells differentiate into Th1
cells, which secrete interferon-g (IFN-g). In contrast, extracellular
pathogens induce the development of Th2 cells, whose cyto-
kines (interleukin-4 [IL-4], IL-5, IL-10, and IL-13) direct immuno-
globulin E- and eosinophil-mediated destruction of the patho-
gens (Mosmann et al., 1986).
DCs regulate CD4+ T cell differentiation through a variety of
molecules that belong to three major families: IL-12, TNF, and
B7. The IL-12 family includes IL-12p70, which controls Th1 cell
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Figure 1. Dendritic Cells
DCs reside in the tissue where they are poised to
capture antigens, be it microbes or vaccines.
DCs recognize microbes (vaccines) and secrete
cytokines (e.g., IFN-a) directly through pattern
recognition receptors or indirectly through stromal
cells that sense microbes (vaccines). Cytokines
secreted by DCs in turn activate effector cells of
innate immunity such as eosinophils, macro-
phages, and NK cells. Activation triggers DC
migration toward secondary lymphoid organs
and simultaneous activation (maturation). These
migratory DCs display antigens in the context of
classical MHC class I and class II or nonclassical
CD1 molecules, which allow selection of rare
antigen-specific T lymphocytes. Activated T cells
drive DCs toward their terminal maturation, which
induces further expansion and differentiation of
lymphocytes. Activated T lymphocytes traverse in-
flamed epithelia and reach the injured tissue,
where they eliminate microbes and/or microbe-in-
fected cells. B cells, activated by DCs and T cells,
differentiate into plasma cells that produce anti-
bodies against the initial pathogen. Antigen can
also drain into lymph nodes without involvement
of peripheral tissue DCs and be captured and pre-
sented by lymph node-resident DCs. Antigen
capture by interstitial DCs (intDCs; orange) will
preferentially lead to generation of humoral immu-
nity, whereas antigen capture by Langerhans cells
(LCs; green) will preferentially lead to generation of
cellular immunity.
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Reviewresponses (Macatonia et al., 1995); IL-23, which controls inflam-
matory CD4+ T cells secreting IL-17 (Th17 cells) (Weaver et al.,
2007); and IL-27, which appears to control IL-10 (Kastelein
et al., 2007). Depending on the nature and time course of activa-
tion (maturation) by different agonists, DCs can express different
molecules from the B7 family: CD80 (B7-1), CD86 (B7-2), ICOS-
ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3, and B7-H4
(Chen, 2004; Greenwald et al., 2005). The B7 family includes
members that can stimulate immune responses and others
that can inhibit them (Chen, 2004). For instance, CD80 and
CD86 bind to both CD28 and CTLA-4. Whereas CD28 delivers
signals for T cells to become effector cells, CTLA-4 delivers
inhibitory signals that suppress their functions (Krummel and
Allison, 1995). Furthermore, through its mode of action, one
molecule might promote both the effector and the regulatory
response, as exemplified by the ICOS ligand. Indeed, ICOS:
ICOS ligand interaction helps the generation of regulatory T
(Treg) cells (Ito et al., 2007) but also appears important in the
stimulation of effector T cells and T cell-dependent B cell
responses (Hutloff et al., 1999). A member of the TNF family,
OX40L (which binds to OX40), shuts down the generation of
IL-10-producing CD4+ type 1 regulatory T (Tr1) cells by DCs
(Ito et al., 2006) but induces the differentiation of proinflamma-
tory Th2 cells secreting TNF and IL-13. As we will discuss later,
DCs and IL-12 are also essential regulators of another type of
helper T cells, so-called T follicular helper (Tfh) cells, which in
turn regulate humoral immunity (Schmitt et al., 2009).
A key cell population involved in the regulation of immune
responses and homeostasis are Treg cells, which include two
major subsets: thymus-derived naturally occurring Treg cells
and periphery-induced Treg cells (Sakaguchi et al., 2010).
Peripherally induced Treg cells are thought to be derived from
naive CD4+ T cells and include Tr1 cells, which mainly produceIL-10 (Roncarolo et al., 2001a), and Th3 cells, which mainly
produce TGF-b (Fukaura et al., 1996). In turn, TGF-b1 synergizes
with IL-21 to generate IgA-plasmablasts, thereby playing a
critical role in the development of mucosal immunity (Dullaers
et al., 2009). The functional specialization of DC subsets in gov-
erning the differentiation of distinct types of Treg cells is currently
a subject of active investigation. Peripheral Treg cells are gener-
ated by DCs that exist at the steady state, i.e., DCs that have not
been activated by microbial stimuli or inflammatory mediators
(Roncarolo et al., 2001b; Yamazaki et al., 2006). These DCs
may not simply be unstimulated or immature. Activation of the
Wnt and b-catenin signaling pathway in DCs has been shown
to promote induced Treg cell production, at least in the mouse
(Jiang et al., 2007). Similarly, in the thymus, production of thymic
stroma lymphopoietin (TSLP) is essential for selection of natu-
rally occurring CD4+CD25hi Treg cells (Watanabe et al., 2005).
Licensing Dendritic Cell Function: A Word on DC
‘‘Maturation’’
DCs exist in distinct functional states including resting and acti-
vated, also known as immature and mature. This is a key feature
of DC biology and relates to the process of DC ‘‘maturation,’’
classically described as the morphological and functional alter-
ations associated with the activation of DCs by microbial stimuli
(e.g., via Toll-like receptor [TLR] agonists) (Trombetta and Mell-
man, 2005). Under steady-state conditions, DCs in peripheral
tissues are most often described as being ‘‘immature,’’ a pheno-
type characterized by the localization of MHC class II molecules
to the late endosome-lysosomal compartment, a low surface
expression of costimulatory molecules, low expression of che-
mokine receptors that trigger migration (e.g., CCR7), and
an inability to release T cell-directed immunostimulatory cyto-
kines (Trombetta and Mellman, 2005). Particularly adept atImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 465
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Figure 2. Distinct DC Subsets Generate Distinct Types of T Cell
Immunity
DC system has two cardinal features: (1) subsets and (2) plasticity. This yields
distinct types of immunity, thereby allowing DCs to cope with protection
against a variety of microbes and maintenance of tolerance to self. Under-
standing these two features is fundamental to develop vaccines that elicit
the desired type of immune responses.
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Reviewendocytosis, immature DCs are often associated with antigen
uptake and sequestration, but not with antigen processing, the
stable accumulation of peptide-MHC complexes, or their effi-
cient presentation to T cells (Trombetta and Mellman, 2005).
Maturation, as triggered by TLR agonists, upregulates surface
MHC class II and costimulatory molecules on the DCs (Trom-
betta and Mellman, 2005) as well as promoting their migration
to draining lymph nodes. It also enhances the ability of the
DCs to interact with antigen-specific T cells, more efficient
antigen processing and presentation, and cytokine release
(Lanzavecchia and Sallusto, 2001). Thus, it is DC maturation,
triggered by adjuvants, that links the innate and antigen-specific
arms of the immune response and thus allows the adaptive
immunity to launch the response against a specific antigen
(Steinman et al., 2003). Because agonist receptors, such as
TLRs, are differentially expressed by different DC subsets and
because different receptors may trigger qualitatively distinct
forms of maturation (e.g., different patterns of cytokine release),
understanding and accounting for DC maturation will be a key
component of any attempt at rational vaccine design because
it will determine the adjuvant used.
Maturation is a simple concept rendered complex by the likeli-
hood that not all mature (or activated) DCs are equivalently
immunogenic (Figure 3). For example, under steady-state condi-
tions, particularly in lymphoid tissue, one can find DC popula-
tions that display at least some of the features of mature DCs
(e.g., elevated surface costimulatory molecules) despite the
absence of overt inflammation or infection. The functional signif-466 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.icance of these cells is unknown but it is not unreasonable to
suspect that tolerogenic DCs may have to acquire the antigen
presentation, migratory, and T cell interaction capacity of mature
DCs in order to induce antigen-specific Treg cells or induce
anergy or T cell apoptosis at high efficiency. As mentioned
above, the priming of Treg cells either in the thymus or in the
periphery may require activation by endogenous mediators
such as TSLP or Wnt, respectively (Watanabe et al., 2005; Man-
icassamy et al., 2010). Whether thesemediators inducemorpho-
logically recognizable maturation in vivo is likely but not known.
However, it is clear that resting or immature DCs can or must be
‘‘activated’’ in some way to induce T cell tolerance; hence, it is
inaccurate to assume that the relevant steady-state DCs are
‘‘immature’’ or resting.
Virtually all DC subsets identified thus far, and discussed
below, are capable of some form of activation, even if not all of
them exhibit the dramatic cellular reorganizations observed for
myeloid and monocyte-derived DCs. Plasmacytoid DCs, for
example, do not dramatically relocalize their MHC class II mole-
cules from lysosomes to the plasma membrane, but respond
functionally (e.g., by interferon secretion) to a range of TLR
agonists to facilitate immunity (Siegal et al., 1999). Because
‘‘mature’’ is usually associated with DCs that have undergone
a morphological transition, we will use the more general term
‘‘activated’’ to describe the responses of DC subsets to adju-
vants or endogenous activators when their phenotypic status
(particularly in vivo) is unclear.
Human Dendritic Cell Subsets
Although activation or maturation is a key factor determining DC
function, the increasing number of distinct DC subsets being
recognized indicates that the distribution of labor among DC
subtypes is likely to be an equally important aspect of how
DCs regulate T cell priming. We will concentrate on DC subsets
that are associated with immunity; however, even in peripheral
tolerance induction, some subsets may be more effective than
others (Siddiqui et al., 2010). Other subsets, notably DCs in B
cell follicular regions, may be most adept at interacting with B
cells, inducing humoral immunity to unprocessed soluble
antigen trapped by these DCs (Wykes et al., 1998).
DC Subsets in Human Blood
The evolution of knowledge of DC subsets has followed parallel
tracks in mice and humans, and understanding them has
become a major focus for many investigators over the past
15 years. Humans andmice display twomajor DC types:myeloid
DCs (mDCs, also called conventional or classical DCs [cDCs])
and plasmacytoid DCs (pDCs). In mice, splenic mDCs were orig-
inally shown to comprise two major mDC subsets with marked
differences in biological function: CD8a+CD11b ‘‘lymphoid’’
DCs and CD8aCD11b+ ‘‘myeloid’’ DCs. CD8a+ DCs are able
to produce large amounts of IL-12 and polarize naive CD4+
T cells toward the Th1 cell phenotype, whereas CD8aDCs pref-
erentially induce Th2 cell responses (Maldonado-Lo´pez et al.,
1999). Although the study of mouse DC subsets can make
important contributions, it is crucial to do such studies with
human cells because subtle but highly relevant differences exist
between the human and mouse immune systems (Mestas and
Hughes, 2004). Thus, to successfully generate human vaccines,
we need to understand the diversity and biology of human DC
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Figure 3. Many Roads Lead to DC
Maturation
DCs exist in distinct functional states: resting and
activated, or immature and mature. Depending
on the signal, DCs will undergo activation/matura-
tion, the quality of which will determine the type of
elicited adaptive immunity.
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Reviewsubsets. DC subsets in the human blood can be distinguished by
differential expression of three surface molecules: BDCA-1
(CD1c), BDCA-2 (CD303), and BDCA-3 (CD141) (Dzionek et al.,
2000).
BDCA-2+ pDCs are considered the front line in antiviral immu-
nity owing to their capacity to rapidly produce high amounts of
type I interferon in response to viruses (Siegal et al., 1999).
They also express high amounts of IL-3Ra chain (CD123) and
ILT-7 (Cao et al., 2006). pDCs are composed of at least two
subsets with different functional properties (Matsui et al.,
2009). They recognize viral components and self nucleic acids
through TLR7 and TLR9, and possibly other as-yet-unidentified
receptors. In their resting state, pDCs might play an important
role in tolerance, including oral tolerance (Liu, 2005). The pDC
presents three remarkable cell biological features to counteract
viral infection: an extensive ER compartment that facilitates
high-capacity secretion of antiviral factors, including type I inter-
ferons; an early endosomal compartment containingMHCclass I
molecules that appears to permit direct vesicular MHC class I
loading for immediate activation of memory cytotoxic CD8+
T cells (Di Pucchio et al., 2008); and a late endosomal compart-
ment containing MHC class II molecules, similar to that found in
mDCs, which facilitates viral antigen presentation to CD4+
T cells. Thus, in both the MHC class I and class II pathways,
pDCs may permit a rapid initial response to viral infections by
utilizing presynthesized stores of MHC class I and II. In addition
to their specialized role in the innate immune response to viruses
(e.g., type I IFN release), pDCs are uniquely capable of rapidly
expanding viral antigen-specific CD8+ T effector cells (Di Puc-
chio et al., 2008). Thus, pDCs are poised to control the progress
of a virus infection through nonspecific blockade of viral replica-
tion by type I IFN and the specific stimulation of adaptive antiviral
responses via cytotoxic CD8+ T cells. pDCs are also critical for
the generation of plasma cells and antibody responses (Jego
et al., 2003). There, two mechanisms are employed to amplify
B cell responses: (1) type I IFN and IL-6 upon viral stimulation
(Jego et al., 2003) and (2) type I IFN-independent mechanism
that is based on their stable expression of CD70 upon CpG acti-
vation (Shaw et al., 2010). Finally, by virtue of their special
capacity for secreting type I IFN, stimulating pDCs may provide
an endogenous adjuvant that could promote the immunogenic
maturation of other DC populations. Thus, strategies designedImmunity 33,to prime pDCs may form the basis of a
next generation of antiviral vaccines.
In human blood there are two types of
mDCs distinguished by reciprocal ex-
pression of BDCA-1 (CD1c) and BCDA-3
(CD141). Human CD141+ DCs represent
the human counterpart of mouse CD8+
DCs. Indeed, they share with mouseCD8+ DCs the high capacity to capture exogenous antigens for
presentation on HLA class I molecules (‘‘cross-presentation’’),
typically reserved for the presentation of peptides from endoge-
nous antigens. CD141+ DCs also share the expression of che-
mokine receptor XCR1 and of adhesion molecule Necl2. Both
human CD141+ DCs and mouse CD8+ DCs utilize XCR1 to
migrate in response to the specific ligand XCL1, which is pro-
duced by NK cells and activated CD8+ T cells (Bachem et al.,
2010; Crozat et al., 2010). Necl2 binds to class I-restricted
T cell-associated molecule (CRTAM), a cell surface protein
primarily expressed by NK cells, NK-T cells, and activated
CD8+ T cells. Thus, mouse CD8+ DCs and human CD141+ DCs
appear well equipped for generation of CD8+ T cell immunity.
In the mouse, gene ablation studies have also shown that the
CD8+ subset plays a disproportionately important role in cross-
presentation (Shortman and Heath, 2010).
The identification of the human counterpart of mouse CD8+
DCs opens the possibility to translate into humans the knowl-
edge generated in the mouse. One should, however, trans-
late mouse data into clinical applications with a critical mind,
because 65 million years of independent evolution have brought
in many nuances that distinguish the human and the mouse
immune systems (Mestas and Hughes, 2004). For example,
other human DCs such as epidermal LCs (Klechevsky et al.,
2008) can also cross-present antigens. Thus, it remains to be
determined whether and how CD141+ blood mDCs are related
to cutaneous mDCs subsets and how all those mDC subsets
cooperate in shaping the adaptive immunity. Blood CD1c+
DCs also display a capacity to cross-present antigens and
to secrete IL-12 (Jongbloed et al., 2010; Poulin et al., 2010).
Also, even if CD141+ DCs are far more adept at cross-presenta-
tion than other DC subsets, ‘‘mass action’’ is a consideration
because CD141+ DCs represent only a small fraction (2%) of
all DCs, at least in the blood. Thus, how these distinct blood
mDC subsets contribute to shaping immunity remains to be
established.
DC Subsets in Human Skin
In human skin, at least two different mDC subsets have been
characterized: epidermal Langerhans cells (LCs) and dermal
interstitial DCs (dermal DCs) (Valladeau and Saeland, 2005).
Over the years, dermal DCs were further subdivided into at least
two subsets: CD1a+ DCs and CD14+ DCs (Valladeau andOctober 29, 2010 ª2010 Elsevier Inc. 467
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ReviewSaeland, 2005). The presence of two dermal DC subsets was
also reported in mice that display a Langerin (CD207) subset in
the dermis (Merad et al., 2008). Epidermal LCs and dermal
CD14+ DCs express different sets of molecules. In particular,
CD14+ DCs express a large number of surface C-type lectins
including DC-SIGN, DEC-205, LOX-1, CLEC-6, Dectin-1, and
DCIR. In contrast, LCs express the lectins Langerin and DCIR.
Furthermore, whereas dermal CD14+ DCs express, at RNA level,
a wide range of TLRs, including TLR-2, 4, 5, 6, 8, and 10 (Kle-
chevsky et al., 2009; van der Aar et al., 2007), LCs exhibit a
more restricted TLR expression including TLR-1, 3, 6, and 10.
Studies suggest that human CD14+ DCs induce naive T cells
to differentiate into cells with properties of Tfh cells (Klechevsky
et al., 2008). Thus, CD4+ T cells primed by CD14+ DCs are able to
induce naive B cells to produce larger amounts of IgM than those
primed with LCs. Remarkably, only CD4+ T cells primed by
CD14+ DCs induce naive B cells to switch isotypes toward IgG
and IgA. Furthermore, CD4+ T cells primed by CD14+ DCs
secrete the chemokine CXCL13, a typical chemokine secreted
by Tfh cells. Taken together, these data suggest that human
dermal CD14+ DCs are specialized for the development of
humoral responses (Klechevsky et al., 2008; Ueno et al., 2007).
Along these lines, human monocyte-derived DCs activated
with ligands of TLR-4, 5, and 7-8, heat-inactivated bacteria, or
CD40 ligand efficiently induce naive CD4+ T cells to become
IL-21 producers, which in turn induce B cells to produce Ig, in
the process mediated predominantly by IL-12 (Schmitt et al.,
2009).
LCs induce more robust proliferation of naive allogeneic CD4+
and CD8+ T cells when compared to CD14+ DCs (Klechevsky
et al., 2008). LCs are also more efficient in cross-presenting
peptides from protein antigens to CD8+ T cells and prime
CD8+ T cells of high avidity when compared to CD14+ DCs.
CD8+ T cells primed by LCs acquire more potent cytotoxicity
than those primed by CD14+ DCs and are able to efficiently kill
target cells, including tumor cell lines that express peptide-
HLA complex only at low amounts (Klechevsky et al., 2008).
Dermal CD14+ DCs showed a poor ability to induce differentia-
tion of CTL effectors. This is not due to the inability to generate
peptide-MHC class I complexes, but rather the inability to induce
the expression of the cytotoxic effector molecules (granzymes A
and B and perforin) on the differentiating T cells. The limited
ability of CD14+ DCs to cross-present proteins such as influenza
matrix protein is not due to a lower ability to process proteins in
general; these cells are indeed more potent at processing MHC
class II-restricted peptides from tetanus toxoid. Themechanistic
basis for why some DCs are more efficient at cross-presentation
remains an important unknown. One possibility is that the
increased concentrations of proteolytic enzymes found within
the endocytic compartments of monocyte-derived DCs destroy
internalized antigens before they have the chance to egress into
the cytosol (McCurley and Mellman, 2010). In general, an atten-
uated capacity for proteolysis is a key feature in enhancing
antigen processing and presentation by DCs, in both the MHC
class I and class II pathways (Delamarre et al., 2005; Trombetta
and Mellman, 2005).
Although CD14+ DCs educate naive CD4+ T cells to become
Tfh-like cells, LCs polarize naive CD4+ T cells into cells secreting
Th2 cell-type cytokines such as IL-4, IL-5, and IL-13. This is468 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.consistent withmouse studies showing the preferential induction
of Th2 cell responses upon delivery of an antigen to the LC-rich
epidermis (Alvarez et al., 2005).
For many years, LCs have been viewed as a paradigm popu-
lation in DC biology. Induction of potent CTL response by LCs
is observed in mouse studies by subcutaneous injections of
peptide-loaded epidermal LCs (Celluzzi and Falo, 1997). Mouse
LCs can actually cross-present antigens to CD8+ T cells in vivo
(Stoitzner et al., 2006). In contrast, several mouse studies, for
example models using herpes simplex virus (HSV), have ques-
tioned the contribution of LCs to the induction of antigen-specific
responses in vivo. These studies attribute the HSV-specific
immunity to CD8a+ DCs, rather than to LCs (Allan et al., 2003).
Further ex vivo studies showed that dermal CD103+ DCs but
not dermal CD11b+ nor LCs were able to present antigens to
naive TCR-transgenic CD8+ T cells ex vivo (Bedoui et al., 2009).
In contrast, all DCs were able to present viral antigens to CD4+
T cells (Bedoui et al., 2009). These results suggest that although
the three cutaneous DC populations acquired viral antigens,
only CD103+ DCs were able to present viral antigens to CD8+
T cells. However, it remains to be determined whether these
differences with regard to the function of LCs between mice
and humans derive from the differences in their immune
systems. One further unknown is the susceptibility of these DC
subsets to virus infection, which may substantially modulate
antigen-presenting function.
Humoral versus Cellular Immunity Regulated by Two
mDC Subsets
Collectively, we hypothesize that two different components
of adaptive immunity, i.e., humoral and cellular, are preferentially
regulated by different mDC subsets, at least in the skin. Thus,
although humoral immunity is preferentially regulated by CD14+
dermal DCs, cellular immunity is preferentially regulated by LCs
(Figure 4). This idea is also supported by mouse studies showing
that dermal DCs upon activation migrate into the outer paracor-
tex just beneath the B cell follicles, whereas LCs migrate into the
T cell-rich inner paracortex (Kissenpfennig et al., 2005). Another
human skin DC subset, dermal CD1a+ DCs, are functionally
intermediate between LCs and CD14+ DCs in our hands.
Whether this DC subset shows a unique asset in the regulation
of immune responses remains to be addressed. It will also be
important to understand whether this paradigm applies to DCs
localized to other peripheral and lymphoid tissues in humans.
Plasticity of DCs and Their Precursors as Key
Determinants of Immunity
In addition to subsets with functional specialization, DCs and
their precursors (monocytes) are endowed with functional plas-
ticity (Figures 2 and 3). DC plasticity needs to be considered at
three levels: (1) response to microbial signals, (2) sensing of
tissue-derived factors, and (3) reciprocal interaction with other
immune cells.
Upon microbial invasion, DCs undergo an initial activation and
maturation process that includes (1) direct signaling by microbial
products and (2) microenvironmental signals delivered by sur-
rounding cells responding to the microbes (Reis e Sousa,
2006; Trombetta and Mellman, 2005). Pathogen-derived signals
transform resting or immature DCs into activated or mature cells
able to launch adaptive immunity. Microbial products can deliver
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Figure 4. Understanding Human Myeloid
Dendritic Cell Subsets for the Rational
Design of DC-Targeting Vaccines
Novel vaccines rely on rational immunological
approaches and aim at activating both the cellular
and the humoral arm. We envision that targeting
antigens and activation of distinct mDC subsets,
with different specializations, will result in the
generation of a broad and long-lived immune
protection. Thus, the most efficient vaccinesmight
be those that will target both LCs and dermal
CD14+ DCs, thereby allowing themaximal stimula-
tion of cellular and humoral immune responses
and the generation of long-term memory protec-
tion. Here we illustrate this concept by using
vaccines against influenza antigens hemagglutinin
(HA) and viral envelope M2 protein to which it
is desirable to elicit antibody responses and
nucleoprotein (NP), which is expected to provide
CD8 epitopes on infected cells, thereby requiring
vaccines that elicit strong cytotoxic CD8+ T cell
responses. In this scenario, vaccines targeting
HA or M2 antigens to interstitial DCs would elicit
humoral response, which are amplified by IL-21-
secreting Tfh cells. Vaccines targeting NP to Lang-
erhans cells would favor CD8+ T cell immunity. The
phenotype of CD4+ T cells (ThX) that provide help
for cytotoxic CD8+ T cells and a cytokine that is
involved in this process (IL-X) remain to be defined.
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Reviewsignals via several molecules, PPRs, belonging to four major
families: (1) C-type lectins, (2) TLRs, (3) NOD-like receptors,
and (4) RIG-I-like receptors. These signals can differentially
modulate DC function, consequently yielding distinct immune
responses (Manicassamy and Pulendran, 2009; Takeuchi and
Akira, 2010). For example, some C-type lectins have signaling
motifs in their cytoplasmic regions and deliver activation or
suppression signals (Reis e Sousa, 2006). Similar to TLR expres-
sion, CLR expression differs between human and mouse
(Flornes et al., 2004). CLRs are also receptors for endogenous
ligands. For example, Mincle and Clec9a (DNGR-1) recognize
damaged cells, Mincle by detecting small nuclear ribonucleopro-
tein (Brown, 2008), which is released from damaged cells, and
Clec9a by detecting as yet unidentified preformed ligand(s)
exposed on necrotic cells (Sancho et al., 2009).
Similarly, different TLRs deliver different activation signals to
DCs (Manicassamy and Pulendran, 2009). Thus, Escherichia
coli lipopolysaccharide (LPS) stimulates DCs through TLR4,
inducing a Th1 cell response by IL-12 secretion, whereas Por-
phyromonas gingivalis LPS activates DCs through TLR2, induc-
ing DCs to secrete IL-10, and eventually resulting in Th2 cell
development (Manicassamy and Pulendran, 2009).
Cytoplasmic sensors include RIG-I-like receptors (the intra-
cellular receptors for RNA viruses) and NOD-like receptors
(NLRs), which are thought to recognize microbial components
(Takeuchi and Akira, 2010). NLRs, such as NALP1, NALP3,
IPAF, and NAIP5, are components of a molecular complex
called the inflammasome (Schroder and Tschopp, 2010). The
inflammasome cleaves substrates, such as pro-IL-1b and
pro-IL-18, to produce mature proteins. NOD1/2 are expressed
in the cytosol of macrophages and DCs, and NALP1 is absent
in germinal center and interstitial DCs while it is highly ex-
pressed in LCs within mucosal surfaces and skin (Schroder
and Tschopp, 2010).The concept of plasticity or flexibility of the DC system is
further exemplified by monocytes and their response to environ-
mental signals. Thus, different cytokines skew the in vitro differ-
entiation of monocytes into DCs with different phenotypes and
function. This might in fact reflect the inflammatory pathway of
DC recruitment and generation in vivo (Domı´nguez and Ardavı´n,
2010; Geissmann et al., 2010). For example, when activated (for
example by GM-CSF) monocytes encounter IL-4, they will yield
IL-4-DCs (Romani et al., 1994). By contrast, after encounter with
IFN-a, TNF, or IL-15, activated monocytes will differentiate into
IFN-DCs (Paquette et al., 1998), TNF-DCs, or IL-15-DCs (Moha-
madzadeh et al., 2001), respectively. This spectrum of DCs
represents immunostimulatory DCs although their in vivo coun-
terparts and precise identities are unknown. Furthermore, it
has been argued that cytokine-driven DCs might not be as
potent in the generation of adaptive immunity as are the DCs trig-
gered directly via microbial signals through PRRs (Joffre et al.,
2009).
Similarly, there is a whole repertoire of DCs that have been
produced in vitro that exhibit immunoregulatory or tolerogenic
functions, for example DCs generated by culturing monocytes
with IL-10 (Levings et al., 2005) or DCs generated in the presence
of vitamin A (Zapata-Gonzalez et al., 2007) or vitamin D3 (Penna
and Adorini, 2000), or DCs activated by E-cadherin-mediated
signaling (Jiang et al., 2007). Should such diversity exist in vivo,
these DC populations might well be important in the context of
DCs’ role in maintaining peripheral tolerance. Tissue-localized
mDCs are also polarized by other cells and their products,
including IFN-a from pDCs, IFN-g from gd T cells and NK cells,
IL-4 and TNF frommast cells, IL-15 and TSLP from stromal cells,
IL-10 from lymphocytes, and Wnt ligands from various cellular
sources (reviewed in Cheng et al., 2010; Ueno et al., 2010). In
principle, these distinct DCs will induce distinct types of T cell
immunity or tolerance.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 469
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as shown by a recent study (Arima et al., 2010). There, TSLP
via activation of NF-kB leads DCs to express OX40L, allowing
the induction of Th2 cell differentiation, whereas the activation
of signal transducer and activator of transcription 6 (STAT6) trig-
gered DCs to secrete chemokines necessary for the recruitment
of Th2 cells. In addition, TSLP signaling limited the activation of
STAT4 and interferon regulatory factor 8 (IRF-8), which are
essential factors for the production of the Th1 cell-polarizing
cytokine IL-12. This Th1 cell-inducing pathway was instead acti-
vated by TLRs and CD40 ligand. Thus, the functional plasticity of
DCs relies on elaborate signal codes that are generated by
different stimuli. As alluded to above, the DC activation or matu-
ration process is more sophisticated than just licensing DCs for
T cell stimulation; it enables DCs to sense their environment and
to assume an activated phenotype that carefully instructs the
qualitative nature of the T cell responses induced.
DCs also have a reciprocal interaction with innate immune
cells. The interaction of DCs with NK, NKT, and gd T cells can
occur in the periphery and the secondary lymphoid organs
(reviewed in Mu¨nz et al., 2005). A recent mouse study suggested
that the activation of NK cells is totally dependent on the interac-
tion with DCs at the secondary lymphoid organs (Lucas et al.,
2007). Activated NK cells enhance their cytotoxicity and capacity
to secrete IFN-g, which render DCs to induce type 1 responses
(Mu¨nz et al., 2005). Mature DCs also activate NKT and gd T cells,
inducing the secretion of IFN-g and IL-4 from NKT cells (Her-
mans et al., 2003) and IFN-g and TNF-a from gd T cells (Leslie
et al., 2002). In particular, activated NKT cells acquire the
capacity to kill tumor cells (Smyth et al., 2002). In return,
CD40L expressed on NKT cells induces the strong activation
of DCs (Mu¨nz et al., 2005).
Thus, subsets and plasticity allow DCs to cope with the chal-
lenges of their environment. These two features also dictate the
quality of the response to vaccine adjuvants and can be har-
nessed for improved vaccination.
Targeting of Dendritic Cell Subsets to Improve Vaccines
Translating the accumulating knowledge on DC subsets and
their unique functional attributes into the design of novel
vaccines is becoming an exciting topic in human immunology.
Active immunization has long been a successful strategy for
the prevention of infectious diseases. The question now is how
to capitalize on our new understanding of DCs to improve
vaccines to the point where they can now also be used more
effectively as therapeutic strategies.
Antigens can be delivered directly to DCs in vivo by using
various types of fusion proteins including cytokines (for example
GM-CSF), chemokines, and toxins, or more specifically anti-
bodies against specific DC surface receptor(s). Studies in mice
demonstrate that the specific targeting of antigen to DCs
in vivo results in considerable potentiation of antigen-specific
CD4+ and CD8+ T cell immunity. The induction of immunity is
observed only when a DCmaturation signal was provided (Boni-
faz et al., 2002; Hawiger et al., 2001); otherwise, tolerance
ensued (Hawiger et al., 2001). Furthermore, in vivo targeting of
murine DC subsets revealed intrinsic differences in antigen pro-
cessing and presentation of different populations (Dudziak et al.,
2007). As discussed earlier, the CD8+CD205+ population was470 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.found to be more adept at cross-presentation of exogenous
antigen on MHC class I than the CD8–33D1+ DC population,
which was somewhat more efficient at MHC class II presenta-
tion. Would targeting antigens to the CD205+ DCs be more effi-
cient at generating CD8+ T cell responses? How do the mouse
studies relate to the human immune system?
Targeting LCs for antigen delivery may be an optimal strategy
for the induction of potent antigen-specific CTL responses.
LC-specific molecule, such as Langerin, can be used as a target
DC receptor (Idoyaga et al., 2008). Dermal CD14+ DCs might
represent the appropriate target for the induction of potent
humoral responses (Figure 4). Selection of an appropriate adju-
vant is also a critical parameter for the induction of the immunity
of the desired type. For example, although TLR-ligands are
widely considered to promote protective immunity against
infectious agents, selecting the appropriate ligand will be critical.
For instance, TLR2 ligation, which promotes the induction of
Treg cells rather than Th1 or Th17 cells (Manicassamy et al.,
2009), does not appear to be a preferred option for cancer
vaccines. Thus, the challenge is tomatch themolecular target on
DCs with the desired immune outcome, mimicking in many ways
the natural role of these DC receptors to fine tune responses
appropriate to the infection. Another strategy to target DCs is
the usage of probiotic lactic acid bacteria to target mucosal
DCs in the gut upon oral administration. Genetic manipulation
of such bacteria could allow coupling of antigen expression
and adjuvant effect of microbial products (Mohamadzadeh
et al., 2008).
DCs originating from a specific tissue have the capacity to
instruct T cells to home back to that tissue (Mora et al.,
2003), and different DC subsets might provide even more
detailed instructions. Furthermore, DCs activated by different
adjuvants could induce T cells with entirely different migration
properties. Addressing this aspect is critical for the design
of vaccines, where optimal sites for T cell migration may vary
in different disease states. For example, whereas vaccines
against melanoma are expected to induce T cells that migrate
into tumor sites including skin, vaccines against influenza virus
are desired to induce T cells to migrate into airway mucosal
surfaces. Therefore, multiple parameters need to be considered
for the development of DC targeting vaccines. These include:
(1) biological function of target DC subsets (induction of
humoral versus cellular immunity), (2) the tissue distribution
and receptors expressed by the target population to ensure
antigen delivery, and (3) the activation receptors expressed
by a given DC subset so as to guide the choice of adjuvant.
Thus, a more complete understanding of the human DC subset
biology will be necessary for the next generation of efficient
DC-based vaccines. Other essential components of a success-
ful vaccine are the selection of antigen and its formulation.
These issues will be discussed below in the context of thera-
peutic cancer vaccines.
Therapeutic Vaccines in Cancer
The prospect of DC-targeted vaccines for the treatment of infec-
tious disease seems promising. Recently, active immunization
against an infectious agent hasbeen shown tohold great promise
in cancer, namely the prevention of HPV-positive cervical cancer
by vaccinating with a recombinant viral capsid protein (Harper
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(1) Vaccines based on antigenwith or without adju-
vant that target DCs randomly. That might result in
vaccine antigens being taken up by a ‘‘wrong’’
type of DCs in the periphery, which might lead to
‘‘unwanted’’ type of immune response. Vaccine
antigens could also flow to draining lymph nodes
where they can be captured by resident DCs. (2)
Vaccines based on ex vivo-generated antigen-
loaded cytokine-driven DCs that are injected
back into patients and (3) specific in vivo DC tar-
geting with anti-DC antibodies linked (by fusion
or conjugation) fused antigens and with DC activa-
tors. (4) Next generation clinical trials will test
optimized DC vaccines combined with patient-
adjusted approaches to block Treg cells and to
break down the suppressive tumor environment.
These therapies will be tested in preselected
patients, thereby leading to personalized therapy.
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not have an obvious etiologic agent, so vaccine approaches in
oncology would have to be therapeutic. In cancer, however,
this task comes with a number of special challenges. First and
foremost, most cancer antigens are nonmutated self-proteins
and thus the repertoire is depleted of high-avidity clones through
negative selection (Finn, 2003). As a result, tolerance must be
overcome, and overcome in the context of patients whose
tumors often induce a tolerogenic milieu.
Numerous approaches for the therapeutic vaccination of
humans with cancer have been developed including autologous
and allogeneic tumor cells (which are often modified to express
various cytokines), peptides, proteins, and DNA vaccines (Fig-
ure 5; reviewed in Dougan and Dranoff, 2009). The observed
results have been variable, yet in many cases, a tumor-specific
immune response could be measured. The clinical efficacy of
therapeutic vaccination in cancer has been questioned (Rosen-
berg et al., 2004) because of the limited rate of objective tumor
regressions observed in clinical trials. At least two issues need
to be considered: (1) the quality of immune responses that these
early cancer vaccines were capable of eliciting and (2) definitions
of clinical endpoints allowing assessment of efficacy.
Concerning the first point, the vast majority of early attempts
at cancer vaccines were performed in the absence of any firm
understanding of DCs or their role in immunization. The targeting
ofuntargetedpeptides,often inweakor ineffective adjuvants,was
(and still is, even in some large ongoing clinical trials) common-
place. It should be clear that such approaches should have had,
a priori, a low likelihood of even generating a robust immune
response, much less one that is therapeutically protective.
Concerning the second point, defining clinical endpoints, the
use of conventional RECIST (response evaluation criteria in solid
tumors) measures to judge efficacy has been challenged by
recent clinical trials testing anti-CTLA4 (ipilumimab) in patients
with stage IV melanoma. There, in a randomized phase III clinical
trial, a 2-fold improved overall survival in patients who received
anti-CTLA4 was observed, but without early indications of tumor
shrinkage (Hodi et al., 2010). In another indication an activeimmunotherapy product, sipuleucel-T (APC8015), based on the
PBMCs activated with a fusion protein of prostate cancer
antigen such as prostatic acid phosphatase PAP with GM-
CSF, resulted in approximately 4 month-prolonged median
survival in phase III trials in patients with prostate cancer (Higano
et al., 2009). In both studies, the analysis of survival curves
shows the separation only after 4–6months, suggesting a certain
delay in the treatment effect, just as one would expect if efficacy
could occur only after the induction or redirection of antitumor
immunity. Many questions remain concerning the therapeutic
mechanisms underlying the results obtained in these trials. Yet,
these studies will help define the basic principles of active immu-
notherapy that set this treatment modality apart from chemo-
therapy, radiotherapy, targeted therapies, and even adoptive
T cell transfer.
Unlike what happens when conventional cytotoxic therapies
are used, the time in which it takes to build tumor immunity
tumors might progress before they actually regress, and tumors
might appear clinically enlarged because of inflammation asso-
ciatedwith active immune responses and lymphocyte infiltration.
Thus, the clinical oncologist’s and drug developer’s expectation
of instantaneous tumor ‘‘melting’’ may have to be managed, as
may also be the case even for many ultimately effective non-
immune-based targeted therapies. Although it may be tempting
to conclude that overall survival may be the only true parameter
of clinical efficacy, such a situation would greatly impede prog-
ress and patient access to new therapies because survival-
based trials can be exceedingly long and costly. The need for
modernized objective, quantifiable response criteria cannot be
overemphasized. In this context, a number of studies demon-
strated in small groups of patients with cancer that a success
or failure of therapeutic vaccination is correlated with the expan-
sion of antigen-specific effector T cells (Paczesny et al., 2004;
Welters et al., 2010). Patients who fail are those in whomantigen-
specific CD4+CD25+Foxp3+ regulatory T cells outnumber the
antigen-specific effector T cells (Welters et al., 2010). Thus,
antigen-specific immune responses should remain among the
key parameters of efficacy. A better understanding of howImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 471
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vaccine, stimulate protective immune responses (Gaucher et al.,
2008; Querec et al., 2009) might contribute to a better under-
standing of immune parameters of vaccine efficacy in cancer
and chronic infections. Indeed, engineering vaccines to precisely
target pathogens and cancer cells requires establishing the laws
of immunity (Yewdell, 2010).
Cell-Based Vaccines
Ex vivo-generated DCs have been used as therapeutic vaccines
in patients with metastatic cancer for more than a decade and
early studies have been reviewed elsewhere (Palucka et al.,
2007). Importantly, a number of clinical studies have shown
that DCs can expand T cells specific for nonmutated self
proteins that are overexpressed in cancer. The analysis of immu-
nological and clinical responses yields three patient groups: (1)
one with no response, (2) one with immunological response
but no clinical responses, and (3) one with both immunological
and clinical responses. This third group is currently the smallest
one but these patients are essential and they need to be studied
in-depth because they will eventually permit us to understand
the immune mechanisms that need to be established to control
tumor growth and eliminate established tumors.
From the analysis of vaccinated patients, four parameters
emerge as critical to understanding whether a vaccine-induced
immune response can be protective: (1) the quality of elicited
CTLs, (2) the quality of induced CD4+ helper T cells, (3) the elim-
ination and/or nonactivation of Treg cells, and (4) the breakdown
of the immunosuppressive tumor microenvironment. Indeed,
CD8+ T cells play important roles in clearance of tumor cells
and infected cells and are the actual drug elicited by vaccines.
The immune responses elicited by the first-generation DC
vaccines might not be of the quality required to allow the rejec-
tion of bulky tumors. For example, the induced CD8+ T cells
might not migrate into the tumor lesions (Appay et al., 2008;
Harlin et al., 2009). Furthermore, low-avidity CD8+ T cells might
not be able to recognize peptide-MHC class I complexes on
tumor cells and/or to kill them (Appay et al., 2008). Finally, the
tumor microenvironment might inhibit effector CD8+ T cell func-
tions, for example, through myeloid-derived suppressor cells
and Treg cells (for review see Gabrilovich and Nagaraj, 2009).
In this context, the quality of CD4+ T cells also represents
a parameter essential for the outcome of immune response.
CD4+ T cells can contribute to antitumor immunity (Pardoll and
Topalian, 1998) through different mechanisms including (1)
provision of help in the expansion of tumor antigen-specific
CTLs (Antony et al., 2005), (2) activation of macrophages at
tumor sites (Corthay et al., 2005), (3) active killing of tumor cells
(Quezada et al., 2010), and (4) the induction of long-termmemory
CD8+ T cells (Sun and Bevan, 2003). However, CD4+ T cells can
also be detrimental, be it in the form of Treg cells that might
dampen elicited CD8+ T cell responses (Roncarolo et al.,
2001a) or protumor type 2 cytokine-secreting CD4+ T cells that
counteract antitumor immunity by promoting tumor develop-
ment (Aspord et al., 2007) and/or by polarizing tumor-associated
macrophages (DeNardo et al., 2009).
The recent progress in immunomonitoring of specific immune
responses in the blood (Palucka et al., 2006) and at the tumor site
should help us address these questions. Modern approaches
including polychromatic flow cytometry rather than the analysis472 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.of a single cytokine (e.g., IFN-g ELISPOT) and/or frequency of
tetramer-positive cells will contribute to a better assessment of
the quality of the immune responses elicited in the patients
(Seder et al., 2008). Indeed, several studies, mostly performed
in the context of HIV vaccines, have led to the conclusion that
a mere measurement of the frequency of IFN-g-secreting CD8+
T cells is insufficient to evaluate the quality of vaccine-elicited
immunity (Appay et al., 2008).
Antibody-Based Vaccines
The experimental success of using DC-specific antibodies to
target antigens to individual DC subsets in conjunction with
appropriately chosen adjuvants has appealing potential for
the design of anticancer vaccines. Combined with a powerful
adjuvant, vaccinating with one or multiple tumor-derived anti-
gens coupled to DC-specific antibodies may amplify existing
responses or break tolerance, enabling the generation of protec-
tive responses. Because such responses would have to beMHC
class I restricted, the approach might be more efficient if
directed at DC populations adapted for cross-presentation,
together with adjuvants that will activate their particular TLRs.
Studies to date demonstrate the targeting of tumor antigens to
DCs and LCs (Flacher et al., 2009) and the generation of thera-
peutic antitumor immunity (Sancho et al., 2008) in animal
models. The BDCA3+ subpopulation of myeloid DCs, as the
likely human homolog of the CD8a+ DC subpopulation, may
be of special interest with respect to their potential for priming
CD8+ T cell responses.
Furthermore, targeting both tumor and control antigens to
human DCs ex vivo can lead to efficient antigen presentation
and generation of CD4+ T cell (Birkholz et al., 2010) and CD8+
T cell (Bozzacco et al., 2007; Klechevsky et al., 2010) responses.
Importantly, certain lectins, including Dectin-1, LOX-1, and DC-
SIGN, as well as other DC surface molecules (e.g., CD40), also
provide activation signals (Brown, 2006; Delneste et al., 2002;
Figdor et al., 2002; Geijtenbeek et al., 2004). They can thus be
exploited for both antigen delivery and activation pathway in
a single targeted vaccine. The therapeutic success of these
vaccines will build on the recent knowledge and progresses in
our understanding of the biology of human DC subsets, cuta-
neous mDCs in particular.
A major challenge of this approach will be achieving not just
T cell responses, but T cell responses that are sufficiently robust
and long lasting so as to be clinically active. In the case of
cancer, however, it will be possible to treat patients repeatedly
and with more aggressive adjuvant combinations than is tradi-
tionally the case when developing prophylactic vaccines for
infectious agents. In addition, it will almost certainly be beneficial
to combine any such vaccination approaches with other agents,
both immune and nonimmune, as discussed below.
Other antigen delivery systems are also under active investiga-
tion, particularly viral vector based. However, less is known
regarding how such vectors enable antigen and adjuvant
delivery to DCs.
The Problem of Antigen Selection
Another major challenge remains the selection of antigen. The
problem is relatively straight forward for prophylactic vaccines,
assuming one understands which epitopes are neutralizing,
expressed during human infection, and immunogenic. In the
case of cancer antigens, the choice is less clear.
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gens and (2) shared self-antigens (Parmiani et al., 2007). The
choice between these types of antigens for vaccination could
be viewed as choice between inducing immunity (mutated anti-
gens, antigens not expressed during negative selection in the
thymus) or breaking tolerance and inducing autoimmunity (over-
expressed antigen, differentiation antigens). The debate about
which type of antigen will be most effective is still open and will
probably remain open until optimized delivery vehicles and adju-
vants are developed for use in humans. The presumed advan-
tages of mutated antigens are based on their potential to be
recognized as non-self by the immune system and their potential
resistance to negative selection in case the mutated protein is
essential for cell survival, such as the B-Raf V600E epitope in
melanoma (Parmiani et al., 2007). Furthermore, mutated anti-
gens may select T cell receptors of higher affinity than shared
antigens (resulting from the absence of thymic-negative selec-
tion) and minimize the prevalence of antigen-specific Treg cells
(unless the tumor has already induced self-tolerance in the
periphery) (Parmiani et al., 2007).
An example of a very potent antitumor and autoreactive
response against self-antigen is provided by studies on paraneo-
plastic diseases and onconeuronal antigens (Darnell, 1994).
Onconeural antigens that are normally expressed in immune
privileged sites, such as neurons, can also be expressed in
some cases of breast and ovarian cancer. In these patients a
strong antigen-specific CD8+ T cell response is generated
(Albert et al., 1998), which provides effective tumor control but
also autoreactive neurologic disease, paraneoplastic cerebellar
degeneration. It is also the case that in melanoma patients, the
existence of robust T cell responses to tumor-associated anti-
gens (even shared antigens) is common (Nagorsen et al., 2003).
Thus, immunity has occurred, it is just not protective, because of
either T cell anergy or Treg cell prevalence. The example proves,
however, that it is possible to generate T cell responses, even
endogenously, to tumor antigens. Indeed, recent results have
demonstrated that antigen-specific T cells accumulate within
tumor beds in melanoma patients (Rosenberg and Dudley,
2009). A vaccine would try to amplify or redirect these responses
to therapeutic efficacy.
Various groups have attempted to rank the potential of the
numerous cancer-associated antigens that have been described
to date (Cheever et al., 2009). In the absence of objective data in
humans, it is difficult to make such assessments, so another
approach has been to score either the expression of genes giving
rise to tumor antigens or the physical presence of individual
peptide-MHC class I complexes expressed at the surface of
tumor cells. To obtain optimal coverage, even for a tumor in an
individual patient, it may be necessary to immunize with several
antigens simultaneously, although a single strong response
may be sufficient. It is also possible that the best antigens will
not be abundant as peptides at the tumor cell surface, and
therefore not detectable by biochemical approaches. Absent
approaches that enable the DC targeting of complex mixtures
of tumor antigens, it seems most reasonable to begin this effort
by using those antigens that can be objectively identified in the
hope that improved delivery approaches and adjuvants will yield
positive, protective immune responses. Focused preclinical and
clinical studies should be employed to test this hypothesis.Thus far, most focus has been placed on protein antigens
whose peptides can be presented on the cell surface in
complexes with classical MHC molecules (Townsend et al.,
1985). However, tumors also express altered lipids and sugars
that are presented by CD1 molecules (Hava et al., 2005). These
can also be harnessed for improved vaccination, for example
NKT cells that are thought to recognize lipid antigens can
generate protective response with IFN-g secretion (Fujii et al.,
2002). Accordingly, injection of cancer patients with DCs loaded
with NKT cell ligand alpha-galactosyl-ceramide leads to sus-
tained expansion of antigen-specific T cells (Chang et al., 2005).
A potentially interesting approach in the selection of antigen
targets is suggested by the possibility that tumors are main-
tained by specialized subpopulations of ‘‘cancer stem cells’’
(Lobo et al., 2007). Although the definition and identity of these
cells remains highly controversial, tumor cells that routinely
survive conventional chemotherapy or targeted therapies are
the ones that are responsible for tumor relapse and death.
If these cells have special properties, or even if not, combining
vaccine approaches with nonlymphoablative front line therapies
may provide an optimal setting for generating protective immune
responses.
Antigen Formulation
An additional important problem is the form of antigen that
should be delivered in the context of a vaccine, either preventa-
tive or therapeutic. Although peptides have often been used for
immunization, as free entities, peptides have poor pharmacoki-
netic properties and are rapidly cleared. Coupling them to
carriers helps somewhat, but chemical or genetic coupling to
DC-targeted antibodies would appear the most efficient
approach to get them to their required destinations. The use of
peptides, of course, may presuppose the identification of rele-
vant T cell epitopes, so conceivably the use of proteins may be
preferable, or protein-peptide mixtures contained within an anti-
body-targeted carrier device (e.g., nanoparticle), which would
enable the use of multiple potential antigens. In this context,
recent studies indicate improved immunogenicity when viral
antigens from HPV (Kenter et al., 2009) or HIV (Pialoux et al.,
2001) are delivered in the form of long peptides together with
adjuvants.
A further consideration is antigen stability. DCs exhibit a
remarkably attenuated capacity for protein degradation, which
serves to extend the longevity of internalized antigens, enabling
a constant supply of endogenously produced peptides for
loading on to bothMHC class I and class II molecules (Delamarre
et al., 2005). The simple rule, then, is that antigens (even endog-
enous ones) that are long lived are generally better than antigens
that are more rapidly degraded (Delamarre et al., 2006). The
extracellular and intracellular fates of antigens therefore will
matter, and attention needs to be paid toward providing admin-
istered antigens in a form that maximizes half life.
Are DCs Enough?
In view of the remarkable diversity of suppressive pathways
present in patients with metastatic cancer, any durable clinical
response elicited by vaccination is already an achievement.
However, to improve the outcomes, DC vaccines need to be
combined, in particular for patients at advanced stages, with
other therapies that offset the suppressive tumor environmentImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 473
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regimens will involve several intervention strategies that target
different pathways. In particular, blocking antibodies or soluble
receptors can be exploited for the blockade of suppressive cyto-
kines in the tumor microenvironment, for example IL-10 (Moore
et al., 2001), IL-13 (Terabe et al., 2000), or TGF-b (Li et al.,
2006). Tumor cells can often express surface molecules that
inherently suppress T cell activity, notably PD-L1, which comes
up especially in tumors that express oncogenic mutations in the
PI3-kinase pathway. Antibodies to PD-1 on activated T cells, or
to PD-L1, might thus reverse T cell exhaustion or anergy (Pilon-
Thomas et al., 2010), and in early clinical studies, treatment with
anti-PD1 exerts some beneficial clinical effect (Brahmer et al.,
2010). It is a common observation in melanoma (and other
cancers) that patients exhibit pre-existing T cell responses
without a vaccine ever having been purposefully administered.
These T cells are not protective, or at least not sufficiently
protective, despite the fact that they can often be recovered
from tumor beds (Rosenberg and Dudley, 2009), suggesting
that reactivation strategies may be useful on their own.
These examples emphasize that DCs may not be enough, and
in some cases, may not even be strictly necessary, at least from
the treating physician’s point of view. An endogenous vaccine
may be created by necrotic or apoptotic death of tumor cells
after chemotherapy or targeted therapy, where tumor antigens
released in conjunction with ‘‘danger signals’’ from the dying
cells are internalized by infiltrating DCs and then presented to
T cells. A further therapeutic vaccine may help amplify these
responses, or perhaps retool them to bemore immunoprotective
than immunoregulatory, but a more effective approach in such
instances might be to target the T cells themselves. This is the
goal of anti-CTLA4-based therapies (Peggs et al., 2009).
Conceivably, antibodies to PD1-PDL1 might also achieve this
goal, and in a fashion with less autoimmune toxicity, because
only those T cells encountering their cognate antigen in the
context of PD1-PDL1 interactions would be stimulated.
Just as different tumors are currently treated with different
combinations of cytostatic drugs and targeted therapies, we
foresee the development of clinical protocols combining DC
vaccines with individualized adjunct therapies, most probably
those involving nonlymphoablative cytotoxic or targeted thera-
pies (Figure 5). In melanoma, the recent demonstration of
dramatic but transient responses in patients expressing the
V600E oncogenic mutation with a specific B-Raf inhibitor (Boni
et al., 2010) creates a remarkable opportunity to implement
just such combination therapies. For such complex therapies
to be designed rationally, however, careful attention will have
to be paid to profiling the immunological status of individual
patients and their tumors before, during, and after therapy.
Patient selection and immunological markers attesting to the
effects of a given therapeutic attempt will be key to under-
standing why an approach does or does not work.
We Have a Dream
Studies performed in the last decade have highlighted the
commonalities and uniqueness of the various DC subsets. This
new knowledge represents a fertile ground to work on to design
better strategies for intervening in numerous clinical situations.
The capacity of LCs and CD14+ DCs to preferentially prime474 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.cellular immunity and humoral immunity, respectively, has signif-
icant implications, most particularly in the context of novel
human vaccines. Thus, targeting LCs will be important for the
design of vaccines that aim at eliciting strong cellular immunity.
Such vaccines might be particularly useful at preventing,
and perhaps even treating, chronic diseases including viral
(HIV, hepatitis C virus), bacterial (mycobacteria), and parasitic
(malaria) diseases, as well as cancer. Themost efficient vaccines
might actually be those that will target both CD14+ DCs and LCs,
thereby allowing the maximal stimulation of both humoral and
cellular immune responses. In this regard it is intriguing to con-
sider that one of the most effective vaccines, smallpox vaccine,
acts through a combination of strong cellular and humoral
immunity and requires scarification of the skin, a procedure
that injures both epidermis and dermis and that is likely to mobi-
lize and activate LCs as well as dermal DCs. Likewise, one of the
most potent vaccines ever generated against yellow fever
(YF17D) activates multiple DC subsets (Querec et al., 2006)
and leads to integrated immune response that includes both
humoral and cellular immunity (Gaucher et al., 2008).
We foresee that the improved vaccines that target DCs will
permit us to treat and prevent many chronic diseases, and like-
wise, manipulation of DCs will also permit us to dampen overly
enhanced immune responses as occurs in allergy and autoim-
munity possibly by turning on regulatory mechanisms.ACKNOWLEDGMENTS
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